The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells.
about
Cyclin-dependent kinase inhibitor therapy for hematologic malignanciesChronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted AgentsTargeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to dateTherapeutic targeting of replicative immortalityGenetic abnormalities in chronic lymphocytic leukemia: where we are and where we goTargeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik.MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanismTargeting cell cycle regulators in hematologic malignancies.Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signalingCyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells.Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia.Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimeticsThe proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activityEmerging drug profile: cyclin-dependent kinase inhibitorsTargeted therapy in chronic lymphocytic leukemia: past, present, and future.Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancerChronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors.Apoptosis inducers in chronic lymphocytic leukemia.Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.Dinaciclib for the treatment of breast cancer.Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia.Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner.New emerging therapies in the management of chronic lymphocytic leukemia.Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression.CDK9 inhibitors in acute myeloid leukemia.
P2860
Q24561485-F7D30D5C-E417-4C3A-8015-E71BB60301F4Q26764833-3A55F76C-CE55-4F7E-8D60-70FF31674429Q26798062-F4E8616B-94FE-41FF-A68B-CEE4BFE8BF42Q27027457-742860F6-64BD-4770-95AF-E2960CD4DEC1Q33744997-085CB544-896E-45EA-A304-285AE8BADF81Q34056627-E7293A19-DFB7-439A-9B2B-C54103C1342DQ34301314-6F47AB11-F784-49D2-B4C4-86EFB4C49BD3Q34393767-82C46176-FFF6-4668-A5F1-69C97B3F3D62Q35334436-C65F9771-0B9E-46D8-BDD8-4DDDDCE3B691Q35550068-1861BDA6-FB5C-414F-A5E2-9324B9849CFAQ35634885-5077D038-BB56-4951-B4B7-1DA5711BCED1Q35852684-ECECB909-4CB9-42C9-AE66-1ED77C94BEECQ36000944-25F3F903-A99E-4898-BC84-72A01B649E20Q36020882-D07A13A5-AC36-4C1C-BAD3-747AA360EB9BQ36231912-93C36BAF-936A-4D3E-8D39-70B799BDFEC5Q36815262-6334B5A3-80EC-4BC1-BAFB-E7DB21ECE1F7Q37063908-C4CA9CCE-5538-4770-B0FB-ACC9A2136A52Q37185372-574DBD70-2290-4199-B3FA-A857DE87FAEDQ37430243-4A32F177-6D32-46EE-BA73-AA2C527D87D2Q37636710-35A2C99D-0857-43DF-A55E-CB829A5485C9Q38110472-2B0F9D27-CB38-4DE5-81F7-69E503A832E4Q38155343-B8E9CC11-823D-49BB-8237-CE46C0E070CCQ38187815-41408CFD-EE56-4BB5-B005-D61DC1191917Q38237619-A9C76D2F-6EBC-48BE-81B8-A7A93A013F32Q38238282-425508ED-BFCF-47C9-87D6-4DB8A3B063E2Q38263806-A68B75D8-8254-47FB-840C-5E4BB7656D23Q38734002-5CA1AC16-0AD9-4849-972C-60AD6A00B4C8Q38755091-FEB60A8F-C6C8-420A-BF47-6E5016C3DAACQ38865573-B3BBDD02-CA55-49E4-9F88-BA8D78F9F29AQ39023986-F402B3A7-D253-4093-A11A-BFD070F3524FQ50031768-A7A97DED-E938-4E67-B8B2-80F05890322AQ50318294-020DDC37-1C7B-49CC-B2E1-8ABF27973429
P2860
The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The novel cyclin-dependent kin ...... ic lymphocytic leukemia cells.
@ast
The novel cyclin-dependent kin ...... ic lymphocytic leukemia cells.
@en
The novel cyclin-dependent kinase inhibitor dinaciclib
@nl
type
label
The novel cyclin-dependent kin ...... ic lymphocytic leukemia cells.
@ast
The novel cyclin-dependent kin ...... ic lymphocytic leukemia cells.
@en
The novel cyclin-dependent kinase inhibitor dinaciclib
@nl
prefLabel
The novel cyclin-dependent kin ...... ic lymphocytic leukemia cells.
@ast
The novel cyclin-dependent kin ...... ic lymphocytic leukemia cells.
@en
The novel cyclin-dependent kinase inhibitor dinaciclib
@nl
P2093
P2860
P356
P1433
P1476
The novel cyclin-dependent kin ...... ic lymphocytic leukemia cells.
@en
P2093
A J Johnson
A J Wagner
M R Grever
R Bannerji
P2860
P2888
P304
P356
10.1038/LEU.2012.144
P577
2012-05-30T00:00:00Z
P5875
P6179
1048216623